Antibiotic resistance keeps climbing, and one of medicine’s most valuable weapons against stubborn Gram-positive infections is slowly losing its edge. Linezolid, the first clinically approved member of the oxazolidinone class, revolutionized the treatment of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci by attacking bacteria in a way no other antibiotic class had before: it binds to the 50S ribosomal subunit and blocks the very first step of protein synthesis. But years of heavy clinical use have bred resistance, and the drug carries a worrying side effect in the form of myelotoxicity, the suppression of bone marrow activity. Only two oxazolidinones, linezolid and tedizolid, are currently approved for multidrug-resistant tuberculosis, leaving an enormous gap for newer, safer analogues. A new computational study published in Discover Chemistry by Rupinder Preet Kaur and Sanjana Manjh of Guru Nanak Dev University in India sets out to close that gap, using quantitative structure-activity relationship (QSAR) modelling and molecular docking to identify which of thirty-one pyridine-based oxazolidinone derivatives deserve a place at the top of the synthesis queue.
The research team focused on 3-(pyridine-3-yl)-2-oxazolidinone derivatives, a family of compounds that earlier experimental work by Bo Jin and colleagues had shown to possess antibacterial activity comparable to linezolid, along with better solubility and reduced cytotoxicity. Rather than simply recording those biological observations, the new study converts them into predictive mathematical models that can forecast how structural changes will affect potency against four Gram-positive strains: Staphylococcus aureus (ATCC 25923), Streptococcus pneumoniae (ATCC 49619), Enterococcus faecalis (ATCC 29212), and Staphylococcus xylosus (ATCC 35924). Experimental minimum inhibitory concentration values were converted to pMIC values and used as the dependent variable in a series of regression models built with the genetic algorithm-multiple linear regression (GA-MLR) method, a technique that uses evolutionary search strategies to select the most informative molecular descriptors from a much larger pool.
The technical pipeline behind the models is rigorous. All thirty-one compounds, including linezolid itself, were drawn in 2D and then conformationally analysed with ORCA 6.0 before geometric optimization at the B3LYP/6-31G* level of density functional theory in Gaussian 09, a choice the authors justify because B3LYP delivers reliable equilibrium geometries for semi-rigid organic frameworks without overestimating intramolecular non-covalent interactions. From these optimized structures, the PaDEL-Descriptor software generated a staggering 1,875 molecular descriptors, numerical encodings of everything from branching patterns to electronic charge distribution. After removing intercorrelated descriptors with a cut-off of 0.99, the data were split into training and test sets using two complementary algorithms: the Kennard-Stone method, which deliberately selects the most chemically diverse compounds, and Euclidean distance-based sampling, which distributes compounds according to their average distance in descriptor space. Split ratios of 70:30 and 75:25 were tested for each strain, and the winning combination differed from organism to organism, an instructive reminder that the shape of a bioactivity landscape depends on the target.
The resulting four models all passed stringent statistical scrutiny. Coefficients of determination ranged from 0.7819 for the S. pneumoniae model to 0.9230 for S. xylosus, while leave-one-out cross-validated Q² values spanned 0.6847 to 0.8704, comfortably above the accepted minimum of 0.5. Adjusted R² values tracked closely with the raw R² values, signalling an absence of overfitting, and Y-randomization tests confirmed that the models were not capturing statistical noise. External predictivity was equally strong: the S. xylosus model achieved Q²(F1) and Q²(F2) values of 0.9682 and 0.9574 respectively, with a concordance correlation coefficient of 0.9777 and the lowest test-set mean absolute error of the entire set. Applicability domains were mapped with Williams plots using leverage thresholds, and nearly every compound fell safely within the reliable prediction region, with the few boundary cases retaining low leverage and therefore not undermining model robustness.
Beyond raw statistics, the models tell a coherent chemical story. In the S. aureus model, the Geary autocorrelation descriptor GATS5i, which captures the spatial distribution of atomic ionization potentials over five-bond distances, emerged as the strongest positive contributor to activity, while the count of fluorine atoms (nF) added a smaller but meaningful boost, consistent with fluorine’s ability to tune local electronic and lipophilic properties. Conversely, molecular branching (SC-5) and the WHIM electrotopological descriptor E3s acted as structural penalties, reducing potency. The E. faecalis model highlighted the minimum electrotopological state of oxygen atoms (mindO), pointing to the importance of accessible, charge-rich carbonyl oxygens for hydrogen bonding, while penalizing long-range charge autocorrelation. The S. xylosus model elevated maxHBa, the maximum hydrogen bond acceptor strength, reinforcing the same theme: polar oxygen atoms capable of donating hydrogen-bond acceptance are essential, whereas bulky, over-elongated, or excessively branched three-dimensional architectures are detrimental.
These descriptor-level insights dovetail neatly with the established structure-activity relationships of the oxazolidinone class, in which inhibition depends on specific electronic features, hydrogen-bonding capacity, and minimal spatial demands. The authors distill the message into a design rule for future analogues: combine available hydrogen bond acceptors and planar heterocyclic spacers while avoiding large bulky 3D structures and distant charge accumulations. Compounds bearing fluorine substitutions fared well in both the QSAR statistics and, as the docking results would later confirm, at the ribosomal binding site itself. The models do carry limitations, which the authors acknowledge candidly: predictions are only trustworthy within the applicability domain of the training chemicals, and the 3D descriptors were computed from a single energy-minimized conformation, ignoring solution-phase dynamics and the induced-fit changes that occur when a ligand actually nestles into its biological target.
To connect the statistical models to physical reality, the team docked the ten most potent derivatives into the 50S ribosomal subunit of Haloarcula marismortui, the archaeal crystal structure (PDB code 3CPW) whose peptidyl transferase center closely mirrors that of pathogenic bacteria and which has served as the canonical template for oxazolidinone binding since the linezolid co-crystal was solved. The docking protocol was validated by re-docking the native ligand, yielding an RMSD of 1.6 angstroms, well within the accepted threshold of 2 angstroms. The results were striking: every one of the ten derivatives bound more tightly than linezolid itself, with binding energies ranging from −9.89 ± 0.06 to −11.21 ± 0.04 kcal/mol against the reference drug’s −9.84 ± 0.01 kcal/mol.
Ligand 26 claimed the top spot with a binding affinity of −11.21 ± 0.04 kcal/mol, anchoring itself in the peptidyl transferase center through hydrogen bonds between its oxazolidinone group and the residues G2540 and C2487, carbon-hydrogen contacts with G2102, U2539, A2486, and U2620, pi-alkyl interactions between its methyl group and A2538, and halogen bonding of its fluorine atom with A2486 and C2487. Ligand 24 followed closely at −11.10 ± 0.13 kcal/mol with a nearly identical interaction fingerprint, while ligands 29, 15, 16, 19, 30, and 28 all posted scores between roughly −10.3 and −10.9 kcal/mol. Notably, ligand 26 had registered a high leverage value in one of the QSAR models, marking it as structurally peripheral, yet its excellent docking score suggests a novel scaffold genuinely worth pursuing rather than a statistical artifact. The consistency between the two approaches was one of the study’s most satisfying outcomes: compounds predicted by QSAR to be highly potent also docked favorably, and the fluorinated derivatives that scored well statistically also formed favorable halogen-mediated contacts at the ribosome.
The authors are careful to frame their findings as a starting point rather than a finish line. Static docking, however well validated, cannot capture induced-fit conformational changes, entropic contributions, or solvent-mediated interactions, so the lead candidates will next be subjected to molecular dynamics simulations and binding free energy calculations using MM/PBSA or MM/GBSA methods. There is also a species caveat: although the peptidyl transferase center is highly conserved across archaea, bacteria, and eukaryotes, subtle sequence differences in the ribosomal proteins and rRNA nucleotides of H. marismortui may influence binding affinities in true pathogens such as S. aureus, so future optimization efforts will turn to cryo-EM structures of eubacterial 50S subunits. What the current work delivers, however, is a validated, interpretable computational filter that converts published in vitro screening data into a prioritized shortlist. Because the entire discovery pipeline rests on computational models built from experimental data, the flagged compounds are best regarded as priority candidates for synthesis and subsequent in vitro and in vivo testing, but in a field where every new oxazolidinone represents years of medicinal chemistry, a reliable mathematical shortcut to the most promising structures is a genuinely valuable advance.
Subject of Research: QSAR modelling and molecular docking of pyridine-substituted oxazolidinone derivatives as potential antibacterial agents against Gram-positive pathogens
Article Title: QSAR modelling and molecular docking studies of 3-(Pyridine-3-yl)-2-oxazolidinone derivatives as potential antibacterial agents against gram-positive pathogens
Article References: Kaur, R. P., & Manjh, S. (2026). QSAR modelling and molecular docking studies of 3-(Pyridine-3-yl)-2-oxazolidinone derivatives as potential antibacterial agents against gram-positive pathogens. Discover Chemistry, 3(1), Article 546. https://doi.org/10.1007/s44371-026-00987-w
Image Credits: AI Generated
DOI: 10.1007/s44371-026-00987-w
Keywords: QSAR, molecular docking, oxazolidinone, linezolid, antibiotic resistance, MRSA, Gram-positive bacteria, GA-MLR, 50S ribosomal subunit, medicinal chemistry, drug discovery, antimicrobials
Cite Scienmag News
APA
MLA
Chicago
Bethany Barker. (October 1, 2026). Computational Models Point to Linezolid-Like Antibiotics That Outbind the Original. Scienmag. https://scienmag.com/computational-models-point-to-linezolid-like-antibiotics-that-outbind-the-original/
Bethany Barker. “Computational Models Point to Linezolid-Like Antibiotics That Outbind the Original.” Scienmag, 1 October 2026, https://scienmag.com/computational-models-point-to-linezolid-like-antibiotics-that-outbind-the-original/. Accessed 1 October 2026.
Bethany Barker. “Computational Models Point to Linezolid-Like Antibiotics That Outbind the Original.” Scienmag. October 1, 2026. https://scienmag.com/computational-models-point-to-linezolid-like-antibiotics-that-outbind-the-original/
Copy citation
Download RIS
Tags: 50S ribosomal subunitAntibiotic resistanceantimicrobialsComputational chemistry in antibiotic designDevelopment of new antibiotics for resistant bacteriadrug discoveryGA-MLRGram-positive bacterialinezolidLinezolid analoguesmedicinal chemistrymolecular dockingMolecular docking for antibacterial agentsMRSAMRSA and vancomycin-resistant enterococci treatmentsMultidrug-resistant tuberculosis therapeuticsMyelotoxicity of oxazolidinonesoxazolidinoneOxazolidinone antibioticsPyridine-based oxazolidinone derivativesQSARQSAR modeling in drug discoveryStructure-activity relationship in antibiotic development
